/ Press Release Details /

Botulinum Toxin Market Size Worth $7.16 Billion By 2025 | CAGR: 8.2%

The global botulinum toxin market is expected to grow at growth rate of 8.2% to reach USD 7.16 billion by 2025.

Botulinum toxin (abbreviated as BTX) is produced by Clostridium botulinum, an anaerobic gram-positive bacterium. It acts by interfering with neural transmission and blocks the release of acetylcholine which may cause muscle paralysis. This drug is injected into a patient using a 30-gauge 1-inch needle to the affected muscles. The growth of this industry is majorly attributed to the increasing therapeutic use of botulinum toxin coupled with rising aesthetic surgical procedures. For example, nowadays, botulinum toxins play a very important role in the management of medical conditions such as hypersalivation, focal dystonias, headaches, hyperhidrosis, and hemifacial spasm.

Additionally, rising demand for minimally invasive treatment, increasing pipeline therapeutics, increasing number of plastic surgeons coupled with an upsurge in facial aesthetic procedures and growing awareness regarding botulinum toxin products support the market growth. However, the industry has been stifled by impediments such as misuse of bioterrorism and high risk of side effects. For example, use of this chemical may cause allergic reactions, bleeding, rash, and neck & back pain.

Key Takeaways

Among products, type A segment is considered to generate a major chunk of the global industry captured more than 96% of the revenue share in 2017
Type A products such as Dysport and Botox ate type A product preparation, however, different in the strain of bacterium, diffusion, preparation, and potency testing
Of the different type A products, Xeomin is the lowest revenue generating segment
Companies namely Allergan, Ipsen Group, Medytox, and Metabiologics are some of the key companies operating in this market
The market is categorized as Therapeutic, and Cosmetic applications. Among which, the cosmetic application is accounted for the highest share of the global market
Key companies are actively engaged in introducing novel products to capture large customer base. For instance, In May 2016, Allergan declared the approval of its BOTOX Vista in Japan, which is used for the treatment of Crow’s feet. The approval is expected to fortify the company’s presence in the country.
Likewise, in March 2016, Merz Pharma declared the availability of Xeomin200-unit vial in the U.S. This move is expected to increase sales of the product for the treatment of adult upper limb spasticity.

KEY BENEFITS OF THE REPORT:

In-depth analysis of the key market dynamics
Granular analysis of the current market scenario and expected factors to affect the market
Detailed analysis of the geographic region, regional and county wise analysis
Highlight on the strategies that are being adopted by the key players in this market to stay competitive
Extensive analysis of the key players dominating the market

The scope of this report covers the market by its major segments, which include as follows:

Market Segmentation

MARKET, BY PRODUCT